PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.71%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-2.36%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-17.14%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-16.80%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-17.89%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-17.88%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-17.88%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.00%
Share reduction while 3391.T is at 0.28%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3391.T is at 0.19%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
27.78%
10Y CAGR of 27.78% while 3391.T is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
-5.26%
Negative 5Y CAGR while 3391.T stands at 59.21%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-31.58%
Negative 3Y CAGR while 3391.T stands at 40.22%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 5Y OCF/share CAGR while 3391.T is at 100.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
No Data
No Data available this quarter, please select a different quarter.
99.93%
10Y net income/share CAGR of 99.93% while 3391.T is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
12.21%
Below 50% of 3391.T's 102.09%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-34.86%
Negative 3Y CAGR while 3391.T is 26.23%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
94.36%
Equity/share CAGR of 94.36% while 3391.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
32.39%
Below 50% of 3391.T's 89.51%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-14.03%
Negative 3Y equity/share growth while 3391.T is at 50.52%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Negative near-term dividend growth while 3391.T invests at 76.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
14.81%
AR growth well above 3391.T's 11.90%. Michael Burry fears inflated revenue or higher default risk in the near future.
8.28%
Inventory growth well above 3391.T's 11.98%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
9.75%
Asset growth at 75-90% of 3391.T's 12.48%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
4.09%
50-75% of 3391.T's 6.10%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
113.93%
Debt shrinking faster vs. 3391.T's 4792.86%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
2.04%
SG&A declining or stable vs. 3391.T's 9.22%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.